Reduced bendamustine for elderly patients with follicular lymphoma was written by Masamoto, Yosuke;Shimura, Arika;Kurokawa, Mineo. And the article was included in Annals of Hematology in 2022.Application of 16506-27-7 The following contents are mentioned in the article:
As the outcome of follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin’s lymphoma, has been improved since the introduction of immunochemotherapy, non-lymphoma-related causes of death, including infections, have become increasingly important. Bendamustine is widely used as one of the key drugs of the standard therapy, and characterized by long-term lymphocytopenia as a frequent adverse event, rendering the patients especially vulnerable to various infections. In this study, authors aims to clarify the short-term outcome and toxicities of the reduced bendamustine. Patients underwent bendamustine treatment without dose reduction from the original plan. Elderly patients in this cohort showed promising outcomes with a similar rate of toxicities except for lymphocytopenia. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Application of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem